Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03646123 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 24, 2018
Last Update Posted : December 6, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C).
The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses).
Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening.
Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hodgkin Lymphoma | Drug: brentuximab vedotin Drug: doxorubicin Drug: vinblastine Drug: dacarbazine Drug: G-CSF Drug: nivolumab | Phase 2 |
This study will have three parts.
Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions.
Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL.
Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 255 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects |
| Actual Study Start Date : | January 28, 2019 |
| Actual Primary Completion Date : | November 7, 2022 |
| Estimated Study Completion Date : | June 7, 2026 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part A: A+AVD
Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
|
Drug: brentuximab vedotin
1.2 mg/kg by IV infusion
Other Names:
Drug: doxorubicin 25 mg/m^2 by IV infusion Drug: vinblastine 6 mg/m^2 by IV infusion Drug: dacarbazine 375 mg/m^2 by IV infusion Drug: G-CSF Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
Other Names:
|
|
Experimental: Part B: AN+AD
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
|
Drug: brentuximab vedotin
1.2 mg/kg by IV infusion
Other Names:
Drug: doxorubicin 25 mg/m^2 by IV infusion Drug: dacarbazine 375 mg/m^2 by IV infusion Drug: nivolumab 240 mg by IV infusion
Other Name: Opdivo |
|
Experimental: Part C: AN+AD
Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
|
Drug: brentuximab vedotin
1.2 mg/kg by IV infusion
Other Names:
Drug: doxorubicin 25 mg/m^2 by IV infusion Drug: dacarbazine 375 mg/m^2 by IV infusion Drug: nivolumab 240 mg by IV infusion
Other Name: Opdivo |
- Febrile Neutropenia (FN) Rate (Part A) [ Time Frame: Up to 6 months ]Proportion of patients with treatment-emergent incidence of FN.
- Complete response (CR) rate (Parts B and C) [ Time Frame: Up to 6 months ]Proportion of participants with CR at end of treatment (EOT), according to the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).
- Primary Refractory Disease Rate (Part A) [ Time Frame: Up to 9 months ]Proportion of participants with less than CR or relapse within 3 months of EOT.
- CR Rate (Part A) [ Time Frame: Up to 6 months ]Proportion of patients with CR at EOT.
- Physician-reported Progression Free Survival (PFS) (Part A) [ Time Frame: Up to 2 years ]The physician-reporting PFS is defined as the time from start of study treatment to first documentation of progression per investigator or to death due to any cause, whichever comes first.
- Subsequent Anticancer Therapy Utilization Rate (Part A) [ Time Frame: Up to 2.5 years ]Proportion of patients with subsequent anticancer therapies.
- Mean Dose Intensity (Part A) [ Time Frame: Up to 6 months ]
- Rate of Dose Reduction and Delays (Part A) [ Time Frame: Up to 6 months ]Proportion of patients with dose reductions or delays related to any component of A+AVD.
- Incidence of adverse events (Parts B and C) [ Time Frame: Up to 7 months ]
- Incidence of laboratory abnormalities (Parts B and C) [ Time Frame: Up to 7 months ]
- Overall response rate (ORR) at EOT (Parts B and C) [ Time Frame: Up to 6 months ]ORR is defined as the proportion of participants with CR or partial response (PR) at EOT.
- Duration of response (DOR) (Parts B and C) [ Time Frame: Up to 5 years ]DOR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per LYRIC or death, whichever comes first.
- Duration of complete response (DOCR) (Parts B and C) [ Time Frame: Up to 5 years ]DOCR is defined as the time from the first documentation of complete tumor response (CR) to the first documentation of tumor progression per LYRIC or death, whichever comes first. DOCR will only be calculated for the subgroup of subjects achieving CR.
- Event-free survival (EFS) (Parts B and C) [ Time Frame: Up to 5 years ]EFS is defined as the time from start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever comes first.
- PFS (Parts B and C) [ Time Frame: Up to 5 years ]PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or death.
- Overall survival (OS) (Parts B and C) [ Time Frame: Up to 5 years ]Overall survival is defined as the time from start of study treatment to the date of death due to any cause.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
-
Treatment-naïve, classic Hodgkin lymphoma (cHL) participants
- Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV disease
- Participants enrolling in Part B of the study must have Ann Arbor Stage I or II cH: with bulky mediastinal disease, or Stage III or IV
- Participants enrolling in Part C of the study must have Ann Arbor Stage I or II cHL without bulky disease
- Histologically confirmed cHL according to the current World Health Organization (WHO) Classification
- Bidimensional measurable disease as documented by PET/CT or CT imaging
- Age 12 years or older in the United States. For regions outside of the US, participants must 18 years or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria
- Nodular lymphocyte predominant HL
- History of another malignancy within 3 years of the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk or metastasis or death. Participants with nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 4 weeks of the first study drug dose
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Active cerebral/meningeal disease related to the underlying malignancy
- Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of the first dose of study drug (Grade 3 defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03)
- Current therapy with other systemic anti-neoplastic or investigational agents
- Planned consolidative radiotherapy (Parts B and C only)
- Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity (Parts B and C only)
- Grade 3 or higher pulmonary disease unrelated to underlying malignancy
- Documented history of idiopathic interstitial pneumonia or diffusing capacity of the lung for carbon monoxide <50% predicted
- History of a cerebral vascular event within 6 months of first dose of study drug
- Child-Pugh B or C hepatic impairment
- Grade 2 or higher peripheral sensory or motor neuropathy
- Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD
- Previous treatment with brentuximab vedotin
- Participants who are pregnant or breastfeeding
- Other serious condition that would impair the participant's ability to receive or tolerate the planned treatment and follow-up
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03646123
Show 76 study locations
| Study Director: | Linda Ho, MD | Seagen Inc. |
| Responsible Party: | Seagen Inc. |
| ClinicalTrials.gov Identifier: | NCT03646123 |
| Other Study ID Numbers: |
SGN35-027 |
| First Posted: | August 24, 2018 Key Record Dates |
| Last Update Posted: | December 6, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Brentuximab vedotin Doxorubicin Vinblastine |
Dacarbazine Nivolumab Seattle Genetics |
|
Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Doxorubicin Nivolumab Dacarbazine Brentuximab Vedotin Vinblastine Antibiotics, Antineoplastic Antineoplastic Agents |
Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Immune Checkpoint Inhibitors Antineoplastic Agents, Alkylating Alkylating Agents Immunotoxins Immunoconjugates Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Phytogenic Tubulin Modulators Antimitotic Agents |